Variant

Variant Bio is a private genomics-driven drug discovery company that uses human genetic diversity, deep phenotyping, whole-genome sequencing, multi-omics, and AI/ML to identify and validate novel therapeutic targets. The company partners with globally diverse and historically underrepresented populations to discover genetic variants linked to exceptional health-related traits and disease resistance. Its proprietary VB-Inference platform is used to prioritize causal biology and generate programs across inflammatory, fibrotic, kidney, metabolic, liver, and muscle-related diseases. Variant Bio advances internal and partnered programs using standard drug modalities, including small molecules and biologics, and has collaborations with Novo Nordisk, Boehringer Ingelheim, and Evotec. The company emphasizes ethics and benefit-sharing with participating communities as a core part of its research model.